Breaking News: FDA Approves Treatment for “Off” Periods in Parkinson’s
ARDSLEY, NY (December 27, 2018) — The U.S. Food and Drug Administration (FDA) has approved INBRIJA™, a levodopa inhalation powder developed by Acorda Therapeutics, as a treatment for “off” periods in people with Parkinson’s disease (PD) who are treated with carbidopa/levodopa.
Quick Facts about INBRIJA™:
- INBRIJA™ is the first and only FDA-approved inhaled levodopa for intermittent treatment of “off” periods in people with PD taking carbidopa/levodopa.
- This new treatment is expected to be available in the first quarter of 2019.
For more information about INBRIJA™ and other PD treatments, contact the Parkinson’s Foundation Helpline at 1-800-4PD-INFO (473-4636) or Helpline@Parkinson.org. You can also read more about INBRIJA™ in this press release from Acorda Therapeutics.
More information about ways to manage “off” time can be found in our podcast episode How to Manage Parkinson’s “Off” Time.
###
About the Parkinson’s Foundation
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson’s Foundation has invested more than $400 million in Parkinson’s research and clinical care. Connect with us on Parkinson.org, Facebook, Twitter, Instagram or call (800) 4PD-INFO (473-4636).
About Parkinson’s Disease
Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the U.S. alone.